Moneycontrol PRO

you are here: HomeNewsBusinessCNBC-TV18 CommentsTeva to gain post Ranbaxy's exclusivity loss for Nexium

SHOW NAMES

Trending Topics

business

Teva to gain post Ranbaxy's exclusivity loss for Nexium

Ranbaxy has lost out on its last big drug opportunity in the US market. The US drug regulator has denied the company 180-day exclusivity for the generic version of heart burn drug Nexium. However Archana Shukla reports that Ranbaxy's loss means good times for global rival Teva and Cipla.

first published: Jan 27, 2015 10:22 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347